IDEAYA Biosciences (Nasdaq: IDYA), a precision oncology company, has recruited Daniel Simon to the role of chief business officer.
Mr Simon most recently served as CBO at Revolution Medicines (Nasdaq: RVMD), from 2022 to 2024, and Senior VP at Guardant Health (Nasdaq: GH), from 2015 to 2022.
A specialist in targeted therapeutics, IDEAYA is working on darovasertib, a protein kinase C inhibitor for tumors with GNAQ or GNA11 mutations.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze